Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Tidal Investments LLC

Tidal Investments LLC lowered its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 28.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 90,197 shares of the biopharmaceutical company's stock after selling 35,153 shares during the period. Tidal Investments LLC's holdings in Bristol-Myers Squibb were worth $5,102,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of BMY. Ameritas Advisory Services LLC raised its stake in Bristol-Myers Squibb by 9.4% during the 4th quarter. Ameritas Advisory Services LLC now owns 15,807 shares of the biopharmaceutical company's stock valued at $894,000 after acquiring an additional 1,357 shares during the last quarter. Annex Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb by 6.0% in the fourth quarter. Annex Advisory Services LLC now owns 6,796 shares of the biopharmaceutical company's stock valued at $384,000 after purchasing an additional 384 shares during the period. Diversify Wealth Management LLC raised its stake in shares of Bristol-Myers Squibb by 10.0% during the fourth quarter. Diversify Wealth Management LLC now owns 14,123 shares of the biopharmaceutical company's stock worth $788,000 after purchasing an additional 1,286 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Bristol-Myers Squibb by 4.0% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 8,687 shares of the biopharmaceutical company's stock worth $491,000 after purchasing an additional 332 shares during the period. Finally, Zhang Financial LLC grew its position in Bristol-Myers Squibb by 42.3% in the 4th quarter. Zhang Financial LLC now owns 5,826 shares of the biopharmaceutical company's stock valued at $330,000 after buying an additional 1,732 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Price Performance

BMY stock traded down $0.15 on Monday, reaching $46.88. The company had a trading volume of 8,401,343 shares, compared to its average volume of 13,150,161. The company's fifty day moving average is $51.79 and its 200 day moving average is $55.72. The company has a market cap of $95.40 billion, a P/E ratio of -10.61, a PEG ratio of 2.07 and a beta of 0.39. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($4.40) earnings per share. On average, research analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.29%. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the company's stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.09% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Jefferies Financial Group cut their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. UBS Group cut their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Finally, Wells Fargo & Company increased their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.